

Resource Summary Report

Generated by [RRID](#) on Aug 5, 2026

CD8a Antibody, anti-mouse, PE-Vio® 770, REAfinity™

RRID:AB_2733250

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-119-123, RRID:AB_2733250

Antibody Information

URL: http://antibodyregistry.org/AB_2733250

Proper Citation: Miltenyi Biotec Cat# 130-119-123, RRID:AB_2733250

Target Antigen: CD8a

Host Organism: human

Clonality: monoclonal

Comments: Info: This product is a higher concentration for optimized use in multicolor flow cytometry panels. It replaces product cat # 130-109-327. (RRID:AB_2659499).
Info: This product is a higher concentration for optimized use in multicolor flow cytometry panels. It replaces product cat # 130-109-249. (RRID:AB_2659500).

Antibody Name: CD8a Antibody, anti-mouse, PE-Vio® 770, REAfinity™

Description: This monoclonal targets CD8a

Target Organism: mouse

Clone ID: clone REA601

Antibody ID: AB_2733250

Vendor: Miltenyi Biotec

Catalog Number: 130-119-123

Record Creation Time: 20250819T231639+0000

Record Last Update: 20250820T045036+0000

Ratings and Alerts

No rating or validation information has been found for CD8a Antibody, anti-mouse, PE-Vio® 770, REAfinity™.

No alerts have been found for CD8a Antibody, anti-mouse, PE-Vio® 770, REAfinity™.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Krug A, et al. (2024) Inhibition of choline metabolism in an angioimmunoblastic T-cell lymphoma preclinical model reveals a new metabolic vulnerability as possible target for treatment. Journal of experimental & clinical cancer research : CR, 43(1), 43.

Colucci M, et al. (2024) Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells. Cancer cell.

Martinez-Turtos A, et al. (2022) IRE1 γ overexpression in malignant cells limits tumor progression by inducing an anti-cancer immune response. Oncoimmunology, 11(1), 2116844.